Articles tagged with Drug Discovery
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Scientists from the University of Bath have identified two new families of chemical compounds that inhibit alpha-methylacyl-CoA racemase (MCR) in Mycobacterium tuberculosis, a key enzyme for TB survival. This breakthrough could lead to new treatments for TB and potentially other diseases like prostate cancer.
Researchers at Florida Atlantic University have secured two key grants to investigate targeting the MBLAC1 gene as a new approach to treat glioblastoma, a very aggressive and fast-growing type of brain cancer. The project aims to advance innovative projects that could make a meaningful impact on cancer therapy.
A new computational tool called ColdBrew predicts the likelihood of water molecule positions within experimental protein structures, aiding drug discovery efforts. The tool leverages data on extensive protein water networks, providing insights into how ligands bind to proteins and potentially improving binding sites.
This issue of SLAS Technology features a high-precision microfluidic flow splitter that outperforms commercial alternatives, enabling even flow division and simplifying multi-inlet perfusion. The journal showcases technological leaps in the life sciences, including rapid pathogen detection and AI-driven insights into schizophrenia.
UVA Health received two anonymous $25 million estate gifts to support the Paul and Diane Manning Institute of Biotechnology. The institute will develop new treatments for hard-to-treat diseases with a state-of-the-art biomedical research facility expected to drive economic growth in Central Virginia.
Researchers tackle pressing challenges in drug discovery with innovative approaches, including high-throughput TRIP13 inhibitors and tau aggregation blockers. The journal focuses on advancing life sciences discovery and technology via education, knowledge exchange and global community building.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
Critical Path Institute's Translational Therapeutics Accelerator awards $250,000 to researchers advancing a promising therapeutic pathway for type 1 diabetes. The project aims to address key challenges in T1D treatment, including beta-cell preservation and immune system modulation.
A new study reveals that Rapamycin has a comparable life-extending effect to dietary restriction in eight species of vertebrates. The compound, originally developed as an immunosuppressant, offers similar benefits without the need for caloric restriction.
Scientists have discovered a novel way to block an enzyme involved in regulating blood pressure, called ACE. Ciprofloxacin binds selectively to a different site, blocking angiotensin I but not inhibiting the enzyme's other functions.
The Lieber Institute is developing a new tool called GRAPE that combines generative and predictive AI to find new, more effective treatments for brain disorders such as schizophrenia. The institute is utilizing AWS gen AI and compute services to advance research and store its massive collection of genomic and other data in the cloud.
The Human Exposome Moonshot initiative aims to map the physical, chemical, biological and psychosocial exposures driving 80% of chronic diseases. The exposome project integrates advanced technologies to create a comprehensive understanding of environmental influences on health.
A team of researchers used AI and human collaboration to identify six promising drug pairs against breast cancer cells. The combinations, including simvastatin and disulfiram, showed potential for further research in therapeutic repurposing.
The Phase IIa trial of Rentosertib showed encouraging clinical data, with patients receiving the treatment experiencing significant improvements in lung function compared to placebo. The study also validated the biological mechanism of TNIK inhibition using exploratory biomarkers analyses.
A new study suggests that a drug used to prevent alcohol abuse can also interrupt runaway cell death and inflammation triggered by severe trauma, particularly in female mice. The findings may lead to therapies that could shorten hospital stays and improve survival rates if administered promptly after traumatic injuries.
Researchers found that an inexpensive HIV drug can improve vision in patients with diabetic macular edema (DME) more effectively and at a lower cost than existing treatments. The drug, lamivudine, is taken orally and may represent a game-changing option for millions of patients worldwide.
Researchers at UCLA Health identified a candidate small molecule, DDL-357, that increases concentrations of secreted clusterin, reducing toxic protein phospho-tau and improving mitochondrial function. The drug also improved memory in treated mice in maze-based cognitive tests.
The Center for Research Innovation in Biotechnology (CRIB) has developed a comprehensive database of active pharmaceutical ingredients with evidence of clinical testing. The database provides valuable information on drug discovery and development, including pricing, sponsors, and intended clinical applications.
A team of researchers has discovered a small molecule that can selectively block cell death, which could lead to new treatments for neurodegenerative conditions. By targeting the killer protein BAX, the molecule can prevent excessive cell death in neurons, potentially slowing or halting disease progression.
The Human Exposome is a global scientific effort to understand the environmental factors that underpin disease and health. The Exposome Moonshot Forum aims to chart this exposome, providing usable metrics and data points for targeted public health interventions.
A new generative AI model, DiffSMol, has been developed to generate realistic 3D structures of small molecules with promising drug properties. The study achieved a 61.4% success rate in creating novel molecules, outperforming prior research attempts.
Insilico Medicine will present detailed Phase IIa data on rentosertib, a novel TNIK inhibitor developed using generative AI, for the treatment of idiopathic pulmonary fibrosis (IPF). The company has previously demonstrated encouraging results from its Phase IIa study, showing favorable safety and tolerability across all dose levels.
University of Oklahoma researchers have developed a method to add a single carbon atom to drug molecules, increasing chemical diversity without compromising sensitive structures. This technique, called skeletal editing, has the potential to revolutionize DNA-encoded library technology and reduce healthcare costs.
The Psychedelics journal has expanded its focus to include all psychoactive drugs, challenging traditional classifications and embracing a broader understanding of consciousness-altering substances. This move aims to reveal novel therapeutic applications and deepen human knowledge of the mind.
Andrew Yang will study proteins crossing the blood-brain barrier and their role in brain health, seeking new therapies for neurological diseases. The 2025 Searle Scholar's research could lead to a better understanding of age-related disorders.
Researchers at Carnegie Mellon University have developed a novel FRESH bioprinting technique that enables the creation of microphysiologic systems entirely out of collagen, cells, and other proteins. This advancement expands the capabilities of studying disease and building tissues for therapy, such as Type 1 diabetes.
A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.
Insilico Medicine's Pharma.AI Day 2025 will showcase the latest AI breakthroughs and updates, including precision target discovery engine PandaOmics and generative biologics platform Generative Biologics. The company aims to accelerate drug discovery and advance life sciences research with its proprietary platform.
The University of Missouri is partnering with a consortium to design and license a new research reactor, NextGen MURR, which will produce critical medical isotopes for cancer treatment. The project aims to enhance Missouri's role as a leader in nuclear science and medical research.
Insilico Medicine is a pioneer in generative AI-driven healthcare, showcasing its Pharma.AI platform and pipeline portfolio featuring IND clearance molecules. The company will share insights at Abu Dhabi Global Health Week panel discussions, focusing on longevity and precision health.
A new USC-led study using fMRI reveals the neural mechanisms that contribute to urinary incontinence in stroke survivors. The research found significant differences in brain activity during voluntary versus involuntary bladder contractions, presenting potential pathways for targeted therapies.
Researchers created a promising approach that augments LLMs with graph-based models to generate molecules with desired properties. The method generates molecules with better matching user specifications and valid synthesis plans, outperforming existing LLM-based approaches.
Engineers at University of Bristol spin-out company Impulsonics have created a technology that can move cells using acoustic waves, enabling critical lab tasks to be carried out on a benchtop device. This innovation has the potential to accelerate drug discovery and unlock personalized medicine screening in clinics.
Researchers discovered a mechanism that harnesses immune cells to produce opioids, potentially alleviating chronic pain. Estrogen and progesterone drive this process, which could lead to more effective treatments for women experiencing pain after menopause.
The Ontario Institute for Cancer Research has announced support for five research teams developing new cancer drugs with improved efficacy and reduced side effects. The funded projects will focus on harnessing new insights about cancer biology to stop cancer from spreading and overcome treatment resistance.
A University of Iowa-led study has revealed the unexpected structure adopted by the DNA repair protein RAD52 as it binds and protects replicating DNA in dividing cells. This understanding may help researchers develop new anti-cancer drugs targeting RAD52.
The Mount Sinai Hospital has launched an AI Small Molecule Drug Discovery Center to revolutionize the creation of life-saving medicines. The center will use cutting-edge AI to design and optimize novel therapeutics with unprecedented speed and precision.
Researchers created a thromboinflammation-on-a-chip model that can sustain blood clots for several months and track treatment options. This model reveals critical information on clot resolution and suggests new drug combinations to protect endothelial function in patients with sickle cell disease.
Researchers developed new AI models, InstaNovo and InstaNovo+, to vastly improve accuracy and discovery in protein science. These models excel in tasks such as de novo peptide sequencing, identifying microorganisms, and discovering novel peptides, with implications for personalized medicine, cancer immunology, and beyond.
Researchers have identified new gateways for drugs to modulate proteins regulating cellular activity. These discoveries may facilitate the creation of new medications or improve existing ones, leading to more targeted therapies and reduced side effects.
Researchers at the University of Houston College of Pharmacy have identified a potential therapeutic target to repair injured muscles. They discovered that fibroblast growth factor–inducible 14 (Fn14) plays a crucial role in regulating satellite cell stability and function, which are responsible for muscle growth, repair, and regenerat...
Researchers at University of Illinois Chicago developed a powerful new antibiotic, Lariocidin, which targets ribosomes to prevent bacterial protein production. Its unique structure allows it to evade common bacterial defenses and transporters, making it a promising candidate for treating deadly infections.
A recent study identifies 11 natural compounds that can inhibit the SARS-CoV-2 spike protein, including caffeine, which exhibits high binding stability and excellent solubility. The discovery highlights the potential of natural products in combating COVID-19 and demonstrates the versatility of widely known compounds like caffeine.
The Alliance for Genomic Discovery has completed sequencing 250,000 whole genomes, providing a comprehensive clinical genomic dataset. This data is being leveraged to accelerate drug target discovery and therapeutic research.
Researchers at Osaka Metropolitan University developed an engineered yeast that can produce record-high yields of D-lactic acid from methanol, a key compound used in biodegradable plastics and pharmaceuticals. The optimized yeast strain achieves a 1.5-fold boost in production compared to other methanol-based methods.
Researchers isolated three potent anti-HIV compounds from Daphne pseudomezereum, with EC₅₀ values around 1 nM and IC50 > 5 μM. The findings suggest a promising approach to developing novel drugs with superior anti-HIV activity.
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
The study found that tunneling nanotube-like structures connect cells in the heart, enabling long-distance intercellular communication essential for heart formation. Disruption of these structures resulted in impaired ventricular wall morphogenesis and defective myocardial growth.
Researchers from IOCB Prague have developed a compound that could treat alopecia areata by targeting the immune system. The substance, a series of prodrugs based on derivatives of itaconic acid, has shown efficacy in mice tests and may be administered orally.
Insilico Medicine has secured a $110 million Series E financing to accelerate the advancement of its AI-driven drug discovery pipeline and platform developments. The funds will focus on refining AI models and algorithms, as well as advancing clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment.
A new study reports that Raman spectroscopy, a noninvasive technique, can distinguish between abnormal FCD type II tissue and healthy brain cells with remarkable accuracy. This method could provide real-time guidance for surgeons to more accurately identify and remove affected tissue during surgery.
Dr. Ronald Newbold has been appointed as the permanent CEO of Empire Discovery Institute (EDI), a non-profit drug discovery and development accelerator. With over 30 years of business development experience, Dr. Newbold will lead EDI's growth and expansion, including the addition of new programs and partnerships.
Scientists at Sanford Burnham Prebys discovered novel fragments of future drugs that selectively inhibit the enzyme VHR, which plays a role in controlling the immune system's response to danger. The findings may lead to the development of new therapies for sepsis and septic shock.
Rentosertib, a breakthrough drug candidate for idiopathic pulmonary fibrosis (IPF), has been granted an official generic name by the USAN Council. The drug's development was accelerated using generative AI, identifying TNIK as a promising target and designing small-molecule compounds in just 18 months.
Insilico Medicine has deployed the first bipedal humanoid AI scientist, Supervisor, to aid in data acquisition and generation for training embodied AI systems. The humanoid will assist with lab tours, telepresence, tracking, and supervision, bridging the gap between human-free fully-autonomous robotics facilities.
The Aligning Science Across Parkinson’s (ASAP) initiative offers funding of up to $6M for research community members to develop sustainable tools for Parkinson’s disease research. The funding supports the development of preclinical models, detection reagents, and modulation agents to accelerate therapeutic research.
Researchers have developed a palladium-mediated reaction to precisely modify peptides and proteins, overcoming challenges in bioconjugation. The method targets dehydroalanine-containing peptides and proteins, enabling efficient synthesis of structurally unique peptides.
A new study discovered rare gene variants in Asian Indian people that increase the risk of Type 2 diabetes, providing a window into targeted treatment. The findings suggest that these variants can be used to create personalized medications that target specific proteins or pathways.
Researchers from NUS have pioneered a new catalytic transformation that converts epoxides into fluorinated oxetanes, a coveted class of drug molecules. The discovery potentially opens the door to new medicines and offers a reliable route to incorporate these motifs into the design of novel small-molecule therapeutics.
The collaboration aims to accelerate antibody discovery and development using Harbour BioMed's technology platform and Insilico's AI expertise. The companies will develop next-generation AI-powered antibodies for immunology, oncology, and neuroscience, aiming to deliver innovative therapies with enhanced specificity, efficacy, and safety.